Prevention, Diagnosis, Treatment, Care, and Support: Addressing Drug-Resistant Tuberculosis in Children March 21, 2013 TB in a child is considered a sentinel health event as it signals recent transmission of tuberculosis (TB), which is preventable and curable. A child infected…
by Erica Lessem December 28, 2012, was a historic day for the one million people around the world with strains of tuberculosis (TB) that are particularly difficult to treat. For the first time in forty years, the United States Food…
by Erica Lessem The world has recently called for zero new TB deaths, infections, and suffering, and that voice has been heard. Treatment Action Group (TAG), along with other activists, researchers, clinicians, implementers, policy makers, and foundation and government staff…
Grief Is a Sword: A Eulogy for Spencer Cox; A Global Plan to End AIDS Everywhere but at Home ; On the Edge: Uncertainty Grows over HIV Budgets; Data Deluge at AASLD; Beyond ARVs: Advocacy for Non-AIDS Disease Management; TB Zeroes Campaign Achieves Big Win; TAG Welcomes the FDA Approval of the First New Drug for TB in 40 Years; Help Support Inclusion of Pegylated Interferon on the World Health Organization’s Essential Medicines List; Guide to Clinical Trials for People with Hepatitis C.
Treatment Action Group (TAG) applauds the accelerated approval today of bedaquiline, the first new approved drug to treat tuberculosis (TB) in over forty years, by the U.S. Food and Drug Administration (FDA). The drug has the potential to improve the treatment for multi-drug resistant (MDR) TB, a particularly deadly and hard to treat form of TB that affects over a million people worldwide, and from which only about half of patients who are treated recover.
TAG’s annual review of progress we’ve made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.
Statement of Mark Harrington, Executive Director, Treatment Action Group to the FDA Anti-Infective Drugs Advisory Committee (AIDAC) Hearing on the Use of Bedaquiline (TMC207) for Treatment of Multidrug-Resistant (MDR) Tuberculosis (TB)
On November 13 at the 2012 International Union Against TB and Lung Disease World Conference in Kuala Lumpur, Malaysia, Treatment Action Group (TAG), the Stop TB Partnership, the Sentinel Project on Pediatric Drug-Resistant Tuberculosis, Partners In Health (PIH), and the…
For the seventh year, Treatment Action Group (TAG) and the Stop TB Partnership have published the latest investment data on the state of global tuberculosis (TB) research and development (R&D) funding.
Now in its seventh year, the Treatment Action Group (TAG) publishes the latest investment data and analysis on the state of global tuberculosis (TB) research and development (R&D) funding.